BioInformant

Your Global Leader in Stem Cell Market Research

Home » Archives for Cade Hildreth (CEO) » Page 3

Landmark MSC Trial for Parkinson’s Disease Authorized by U.S. FDA

By Leave a Comment

April 28, 2021, SUGAR LAND, Texas — Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.

The trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson’s patients in such high quantities over repeat treatments. Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each. [Read more…]

The Best Cord Blood Bank of 2021: Which One Should You Choose?

By Leave a Comment

After choosing a name for your newborn, the next decision you’ll need to make is whether or not you want to save their cord blood. It’s a choice you will need to make swiftly, as the window to successfully store your child’s cord blood and cord tissue is a relatively small one.

While there is a lot of information available for expecting parents, sifting through all the options to find the best cord blood bank can be overwhelming, especially if you’re not exactly familiar with all the terms and technology. [Read more…]

Horizon 2020 consortium funding to fuel cell therapy microcarrier development at denovoMATRIX

By Leave a Comment

DRESDEN, Germany, April 29, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced today that it will participate in the new European collaborative project funded by the European Union’s Horizon 2020 research and innovation program.

[Read more…]

5 Strategies To Stay on Top of a Changing Cell Therapy Industry

By Leave a Comment

Author: Jonathan Wofford, General Manager of WellSky’s Biotherapies Division

As operations for cell and gene therapy programs become more demanding and supply chain management becomes more complex, your program may face various challenges adapting to these changes. For example, increasing manufacturing and procedure volumes in combination with new and changing protocols will require the use of more automated, flexible and efficient processes. Tightening regulations will require greater documentation and process control. As cell and gene therapies continue to grow in clinical application, payers, study sponsors, and other agencies will require more data and reporting. [Read more…]

Organicell Announces Positive Results Of Initial COVID-19 Zofin™ Patient Trial In India And Trial Expansion

By Leave a Comment

Miami, FL (April 28, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India.  This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients. [Read more…]

BioInformant's World-Class Clients